AUTHOR AND EDITOR INFORMATION

Section 1 of 11  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• Multimedia
• References

INTRODUCTION

Section 2 of 11  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• Multimedia
• References

Background

Dyshidrotic eczema is a recurrent or chronic relapsing form of vesicular palmoplantar dermatitis of unknown etiology. Dyshidrotic eczema also is termed pompholyx, which derives from cheiropompholyx, which means "hand and bubble" in Greek.

The etiology of dyshidrotic eczema is unresolved and believed to be multifactorial. It is considered a reaction pattern caused by various endogenous conditions and exogenous factors.

Pathophysiology

Several hypotheses have been proposed for the pathophysiology of dyshidrotic eczema. The original hypothesis of sweat gland dysfunction has been disputed because vesicular lesions are not associated with sweat ducts. Patients do not usually have hyperhidrosis. However, note that patients with dyshidrotic eczema have been reported to improve and have fewer relapses after botulinum toxin A injection.

Dyshidrotic eczema may be associated with atopy and familial atopy. Of patients with dyshidrosis, 50% have atopic dermatitis.

Exogenous factors (eg, contact dermatitis to nickel, balsam, cobalt; sensitivity to ingested metals; dermatophyte infection; bacterial infection) may trigger episodes. These antigens may act as haptens with a specific affinity for palmoplantar proteins of the stratum lucidum of the epidermis. The binding of these haptens to tissue receptor sites may initiate pompholyx.

Emotional stress and environmental factors (eg, seasonal changes, hot or cold temperatures, humidity) reportedly exacerbate dyshidrosis. A similar eruption has been reported after intravenous immunoglobulin infusion.

In some patients, a distant fungal infection can cause palmar pompholyx as an id reaction. In one study, one third of pompholyx occurrences on the palms resolved after treatment for tinea pedis. Trichophyton rubrum is the most commonly identified dermatophyte.

Frequency

United States

Dyshidrotic eczema occurs in as many as 5-20% of patients with hand eczema and more commonly occurs in warmer climates and during spring and summer months.

International

Dyshidrotic eczema comprised 1% of initial consultations in a 1-year Swedish study.

Mortality/Morbidity

Dyshidrotic eczema can be severe, resulting in occupational disability and time away from work; however, disability compensation usually is not provided for this condition.

Sex

Male-to-female ratio is 1:1.

Age

Dyshidrotic eczema affects individuals aged 4-76 years; mean age is 38 years. After middle age, the frequency of episodes tends to decrease.

CLINICAL

Section 3 of 11  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• Multimedia
• References

History

Patients complain of pruritus of hands and feet with sudden onset of blisters. Burning pain or pruritus occasionally may be experienced before blisters appear. Episodes vary in frequency from once per month to once per year. Patients may report a variety of factors that possibly are related to eruptions.

• Emotional stress
• Personal or familial atopic diathesis (eg, asthma, hay fever, sinusitis)
• Certain work exposures (eg, cobalt) and/or recreational exposures
• Recent exposure to contact allergens (eg, nickel, balsams, paraphenylenediamine, chromate, sesquiterpene lactones) before condition flares
• Exposure to contact irritants before condition flares
• Recent exposure to costume jewelry (patients with palmar pompholyx and allergic to nickel)
• Recent treatment with intravenous immunoglobulin therapy
• HIV related: Two cases were reported of HIV-positive patients who developed dyshidrotic eczema as an immune reconstitution inflammatory syndrome shortly after highly active antiretroviral therapy.

Physical

Symmetric crops of clear vesicles and/or bullae on the palms and lateral aspects of fingers characterize dyshidrotic eczema (Media Files 1-2, Media Files 5-7, and Media File 9). Feet, soles, and the lateral aspects of toes also may be affected.

• In mildly affected patients, vesicles are present only on the lateral aspects of fingers and, occasionally, involve feet and toes (Media File 9).
• Vesicles are deep seated with a tapiocalike appearance, without surrounding erythema (Media File 2).
• • May become large, form bullae, and become confluent (Media File 8)
  • Typically resolve without rupturing, followed by desquamation


• Hands are involved solely in 80% of patients, feet solely in 10% (Media File 3), and both hands and feet are involved in 10% of patients (Media File 8).
• With long-standing disease, patients' fingernails may reveal dystrophic changes (eg, irregular transverse ridging, pitting, thickening, discoloration).
• Interdigital maceration and desquamation of the interdigital spaces often are present, despite the possible absence of a dermatophyte infection.
• Vesicles and/or bullae may become infected secondarily, and pustular lesions may be present. Cellulitis and lymphangitis may develop.
• The Dyshidrotic Eczema Area and Severity Index recently was developed based on severity grades for the number of vesicles per square centimeter, erythema, desquamation, itch, and the extent of affected areas. The index was found to be a simple standardized method for assessing the condition and was used to assess disease severity and treatment effectiveness in 2 clinical studies. Further evaluation with larger patient groups is needed.

Causes

The cause of dyshidrotic eczema is unknown. The condition often appears related to other skin diseases (eg, atopic dermatitis, contact dermatitis, allergy to ingested metals, dermatophyte infection, bacterial infection, environmental or emotional stress). Several factors may participate in causing dyshidrotic eczema and pompholyx.

• Genetic factors: Monozygotic twins have been affected simultaneously by dyshidrotic eczema. The pompholyx gene has been mapped to band 18q22.1-18q22.3, in the autosomal dominant form of familial pompholyx.
• Atopy: As many as 50% of patients with dyshidrotic eczema have reportedly had personal or familial atopic diathesis (eczema, asthma, hayfever, allergic sinusitis).
• • Serum immunoglobulin E (IgE) level frequently is increased, even in patients who do not report a personal or familial history of atopy.
  • Occasionally, dyshidrotic eczema is the first manifestation of an atopic diathesis.


• Nickel sensitivity: This may be a significant factor in dyshidrotic eczema.
• • Nickel sensitivity was reportedly low in some studies of dyshidrosis patients but significantly elevated in other studies.
  • Increased nickel excretion in the urine has been reported during exacerbations of pompholyx.
  • Ingested metals have been found to provoke exacerbations of pompholyx in some patients.


• Low-nickel diets: These have reportedly decreased the frequency and severity of pompholyx flares.
• • A high palmoplantar perspiration rate has been suggested to result in a local concentration of metal salts that may provoke the vesicular reaction.
  • Contact allergy has been documented in 30% of patients with dyshidrotic eczema.


• Id reaction: Dyshidrotic eczema outbreaks are not always associated with exposure to sensitizing chemicals or metals (eg, chromium, cobalt, carba mix, fragrance mix, diaminodiphenylmethane, dichromates, benzoisothiazolones, paraphenylenediamine, perfumes, fragrances, balsam of Peru, primula plant). Controversy surrounds the possible existence of an id reaction, which is a distant dermatophyte infection (tinea pedis, kerion of scalp) triggering a palmar pompholyx reaction (also termed pompholyx dermatophytid).
• Fungal infection: Pompholyx occasionally resolves when a tinea pedis infection is treated, then relapses when the fungal infection recurs, supporting the existence of this reaction pattern. Of patients who have a vesicular reaction to intradermal trichophytin testing, less than one third have experienced a resolution of pompholyx after treatment with antifungal agents.
• Emotional stress: This is a possible factor in dyshidrotic eczema. Many patients report recurrences of pompholyx during stressful periods. Improvement of dyshidrotic eczema using biofeedback techniques for stress reduction supports this hypothesis.
• Other factors: Isolated reports of other possible causative factors exist, such as aspirin ingestion, oral contraceptives, cigarette smoking, and implanted metals.

DIFFERENTIALS

Section 4 of 11  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• Multimedia
• References

Other Problems to be Considered

Dyshidrosiform pemphigoid
Inflammatory tinea pedis or tinea manus
Palmoplantar pustular psoriasis
Pustular bacterid

WORKUP

Section 5 of 11  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• Multimedia
• References

Lab Studies

• Diagnosis is usually made clinically.
• Bacterial culture and sensitivity exclude secondary infection.
• Blood tests are not usually ordered; however, IgE levels are commonly elevated.

Other Tests

• Use patch testing to exclude allergic contact dermatitis.
• Measuring thiopurine methyltransferase levels allows accurate dosing of azathioprine.

Procedures

• Perform potassium hydroxide wet mount preparation to exclude dermatophyte infection.
• Punch biopsy for hematoxylin and eosin staining usually is not necessary.
• Punch biopsy for periodic acid-Schiff staining may help exclude dermatophytosis in patients with unresponsive disease.
• Use punch biopsy for direct immunofluorescence to exclude bullous pemphigoid.

Histologic Findings

Spongiosis with an epidermal lymphocytic infiltrate and intraepidermal vesicles or bullae are not associated with sweat glands.

TREATMENT

Section 6 of 11  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• Multimedia
• References

Medical Care

Some mildly affected patients experience spontaneous resolution within 2-3 weeks. Biofeedback therapy for stress reduction has succeeded in some patients. Outpatient care is multifaceted.

• The following treatment is appropriate if bullae are present.
• • Use compresses with Burow solution (10% aluminum acetate) in a 1:40 dilution until bullae resolve (usually, within a few days).
  • Compresses with a 1:10.000 solution of potassium permanganate are also effective.
  • Drain large bullae with a sterile syringe, and leave the roof intact.
  • Prescribe systemic antibiotics that cover Staphylococcus aureus and group A streptococci.
• Topical corticosteroids are the mainstay of treatment.
• • Typically, use class I steroids initially, then class II or III steroids.
  • Ointments penetrate skin better than creams; patients may prefer creams during the day.
  • Topical antipruritics with pramoxine are useful.
• Systemic corticosteroids.
• • Either oral prednisone or intramuscular triamcinolone suspension may be used for or severe episodes.
  • Tapering of prednisone can follow intramuscular treatment.
• Some patients may benefit from topical tacrolimus or pimecrolimus. The primary author follows several patients in her practice who are controlled with topical calcineurin inhibitors alone.
• Hand and/or foot UVA therapy (UVA or UVA1 alone or with oral or topical psoralen) improves the eruption and pruritus when administered 2-3 times per week. The dose typically starts at 0.5 J per treatment and is increased by 0.5 J at every other or every third treatment.
• Botulinum toxin A injections may be helpful in some patients.
• For severe refractory pompholyx, azathioprine, methotrexate mycophenolate mofetil, cyclosporine, or etanercept may be helpful. Consider measuring thiopurine methyltransferase levels, which may help guide azathioprine therapy. Accurate dosing avoids both toxicity and underdosing.
• Nickel chelators, such as disulfiram (Antabuse), occasionally are used in nickel-sensitive patients who demonstrate a positive oral provocation test.
• Tap water iontophoresis with pulsed direct may be helpful as adjuvant treatment.
• Khellin, a furanochromone similar to methoxypsoralens, may be used in combination with photochemotherapy (sun exposure) for recalcitrant palmoplantar cases. Khellin, unlike other psoralens, does not induce skin phototoxicity (erythema) and hyperpigmentation of healthy skin after UVA radiation therapy.

Consultations

• Psychologist - For stress reduction using biofeedback therapy and other techniques
• Allergist - For oral provocation test for nickel, cobalt, or chromium salts
• • Oral challenges occasionally are positive in patients who demonstrate negative patch tests to these metals.
  • The test is considered positive if a patient's pompholyx flares after metal is ingested.

Diet

• For nickel-sensitive patients, consider a low-nickel diet for 3-4 weeks.
• • The diet regimen only rarely is successful and is difficult for patients to follow.
  • The diet requires avoiding foods rich in nickel, such as canned foods, foods cooked in nickel-plated utensils, herring, oysters, asparagus, beans, mushrooms, onions, corn, spinach, tomatoes, peas, whole grain flour, pears, rhubarb, tea, cocoa, chocolate, and baking powder.

• For cobalt-sensitive patients, consider a low-cobalt diet that avoids apricots, beans, beer, beets, cabbage, cloves, cocoa, chocolate, coffee, liver, nuts, scallops, tea, and whole grain flour.

Activity

• Bedrest may be necessary if bullae develop on the feet.
• If palmar bullae develop, patients may not be able to work or perform the activities of daily living.

MEDICATION

Section 7 of 11  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• Multimedia
• References

The goals of pharmacotherapy are to reduce morbidity and prevent complications.

Drug Category: Corticosteroids

Have anti-inflammatory properties and cause profound and varied metabolic effects. Modify the body's immune response to diverse stimuli. Topical ointments are more potent but greasier than creams.

Drug Name	Fluocinolone (Fluonid, Synalar)
Description	Ointment is a class II, cream is a class III steroid. High-potency; like all topical steroids, has anti-inflammatory, antipruritic, and vasoconstrictive properties.
Adult Dose	Apply cream or ointment sparingly bid as severity warrants
Pediatric Dose	Apply as in adults
Contraindications	Documented hypersensitivity; herpes simplex infection, fungal, viral, or tubercular skin lesions
Interactions	None reported
Pregnancy	C - Safety for use during pregnancy has not been established.
Precautions	May cause adverse systemic effects if used over large areas, denuded areas, on occlusive dressings, or during prolonged treatment periods; prolonged use may result in thinning of skin

Drug Name	Prednisone (Deltasone, Meticorten, Orasone)
Description	Immunosuppressant for treatment of autoimmune disorders; may decrease inflammation by reversing increased capillary permeability and suppressing PMN activity.
Adult Dose	0.5-1 mg/kg/d PO qam; taper over 2 wk
Pediatric Dose	Administer as in adults
Contraindications	Absolute: Systemic fungal infection, herpes simplex keratitis, hypersensitivity (usually with corticotropin, occasionally with IV preparations) Relative: Hypertension, active TB, CHF, prior psychosis, positive intermediate purified protein derivative test result, glaucoma, severe depression, diabetes mellitus, active PUD, cataracts, osteoporosis, recent bowel anastomosis, and pregnancy
Interactions	Ketoconazole, erythromycin, clarithromycin, estrogens, and birth control pills increase levels Aminoglutethimide, phenytoin, PB, rifampin, cholestyramine, and ephedrine decrease levels Levels of potassium-depleting diuretics (due to potentiation of potassium loss and digitalis toxicity) and cyclosporine may increase; levels of isoniazid, insulin (resistance is induced), and salicylates may decrease; monitor anticoagulant therapy and theophylline levels
Pregnancy	B - Usually safe but benefits must outweigh the risks.
Precautions	Abrupt discontinuation may cause adrenal crisis; hyperglycemia, edema, osteonecrosis, myopathy, peptic ulcer disease, hypokalemia, osteoporosis, euphoria, psychosis, myasthenia gravis, growth suppression, and infections may occur

Drug Name	Betamethasone (Celestone, Soluspan)
Description	For severe acute episodes. Rapid onset (within 1 h) with 72-h duration. For inflammatory dermatosis responsive to steroids. Decreases inflammation by suppressing migration of PMN leukocytes and reversing capillary permeability.
Adult Dose	5-9 mg IM as single dose
Pediatric Dose	Not advised
Contraindications	Absolute: Systemic fungal infection, herpes simplex keratitis, hypersensitivity (usually with corticotropin, occasionally with IV preparations) Relative: Hypertension, active TB, CHF, prior psychosis, positive intermediate purified protein derivative test result, glaucoma, severe depression, diabetes mellitus, active PUD, cataracts, osteoporosis, recent bowel anastomosis, and pregnancy
Interactions	Aminoglutethimide, phenytoin, PB, rifampin, cholestyramine, and ephedrine decrease levels Levels of potassium-depleting diuretics (due to potentiation of potassium loss and digitalis toxicity) and cyclosporine may increase; levels of isoniazid, insulin (resistance is induced), and salicylates may decrease; monitor anticoagulant therapy and theophylline levels
Pregnancy	C - Safety for use during pregnancy has not been established.
Precautions	Increases risk of multiple complications, including severe infections; hyperglycemia, edema, osteonecrosis, myopathy, peptic ulcer disease, osteoporosis, euphoria, psychosis, myasthenia gravis, growth suppression, and infections are possible complications If given by injection, bruising, infection, cold abscess, temporary depression in skin, and temporary discoloration of skin (usually lightened) may occur at injection site

Drug Name	Triamcinolone (Aristocort)
Description	For inflammatory dermatosis responsive to steroids; decreases inflammation by suppressing migration of PMN leukocytes and reversing capillary permeability. Long duration, 4-6 wk.
Adult Dose	40-60 mg IM as single dose
Pediatric Dose	2.5-15 mg (10 mg/mL or 40 mg/mL solutions) IM single dose; repeat prn
Contraindications	Absolute: Systemic fungal infection, herpes simplex keratitis, hypersensitivity (usually with corticotropin, occasionally with IV preparations) Relative: Hypertension, active TB, CHF, prior psychosis, positive intermediate purified protein derivative test result, glaucoma, severe depression, diabetes mellitus, active PUD, cataracts, osteoporosis, recent bowel anastomosis, and pregnancy
Interactions	Aminoglutethimide, phenytoin, PB, rifampin, cholestyramine, and ephedrine decrease levels Levels of potassium-depleting diuretics (due to potentiation of potassium loss and digitalis toxicity) and cyclosporine may increase; levels of isoniazid, insulin (resistance is induced), and salicylates may decrease; monitor anticoagulant therapy and theophylline levels
Pregnancy	C - Safety for use during pregnancy has not been established.
Precautions	Multiple complications may occur, eg, severe infections, hyperglycemia, myopathy, peptic ulcer disease, osteoporosis, euphoria, psychosis, myasthenia gravis, growth suppression If given by injection, bruising, infection, cold abscess, temporary depression in skin, and temporary discoloration of skin (usually lightened) may occur at injection site

Drug Category: Immunosuppressives

Drug Name	Pimecrolimus, topical (Elidel)
Description	For short-term treatment or intermittent long-term treatment in unresponsive or intolerant cases. Inhibits T-lymphocyte activation. Available at 1% cream
Adult Dose	Apply bid to affected areas; discontinue after clearing
Pediatric Dose	<2 years: Not indicated >2 years: Administer as in adults
Contraindications	Documented hypersensitivity; local infection at treatment site; Netherton Syndrome; children <2 y; immunodeficiency syndromes; caution in herpes simplex or varicella-zoster virus infection, eczema herpeticum, and erythroderma
Interactions	None reported
Pregnancy	C - Safety for use during pregnancy has not been established
Precautions	Serious adverse reactions include varicella-zoster or herpes simplex virus infection, eczema herpeticum, angioneurotic edema, and anaphylaxis; common adverse reactions include skin burning, flulike symptoms, headache, nasopharyngitis, cough, pyrexia, erythema, hypersensitivity reaction, skin infection, herpes simplex, skin papilloma, erythema, and pruritus Do not use with occlusive dressings; limit use to affected skin; avoid continuous long-term use; reevaluate if symptoms persist >6 wk; causal relationship not established for malignancies, including skin cancer and lymphoma

Drug Name	Methotrexate (Rheumatrex, Folex)
Description	Unknown mechanism of action in treatment of inflammatory reactions; may affect immune function. Ameliorates symptoms of inflammation (eg, pain, swelling, stiffness). Antimetabolite that inhibits DNA synthesis and cell reproduction in malignant cells; may suppress immune system. Satisfactory response seen within 3-6 wk following administration. Adjust dose gradually to attain satisfactory response.
Adult Dose	Administer 1. 5- to 10-mg test dose; check CBC count in 1 wk; if results are normal, continue weekly 1-time 7.5-mg doses (may split if GI upset, ie, 8am, 8pm, 8am dosing); increase dose by 2.5 mg/wk each month (may taper by 2.5 mg/wk each month when decreasing dose to lowest possibility)
Pediatric Dose	Not recommended
Contraindications	Absolute: Pregnancy or desire to get pregnant, active peptic ulcer, alcoholism, primary/secondary immunodeficiency, blood dyscrasias, active hepatitis, cirrhosis, chronic renal failure, and active infections Relative: History of excessive ethanol intake or substance abuse, increased LFT results, recent hepatitis, diabetes mellitus, obesity, history of heritable liver disease, unreliable patient, CrCl <50 mL/min, males contemplating conception (must discontinue for 3 mo)
Interactions	Salicylates, NSAIDS, dipyridamole, probenecid, retinoids, ethanol, triamterene, pyrimethamine, sulfonamides, TCN, chloramphenicol, penicillin or other broad-spectrum antibiotics, trimethoprim, dapsone, theophylline, phenytoin, phenothiazines, barbiturates, and nitrofurantoin (impair folic acid absorption), ascorbic acid, phenylbutazone, cyclosporin, aminoglycosides
Pregnancy	D - Unsafe in pregnancy
Precautions	Monitor CBC counts, differentials, renal panel, U/A, LFTs monthly; creatinine clearance baseline recommended for patients >50 y; monitor more frequently during initial dosing, dose adjustments, or if risk of elevated MTX levels (eg, dehydration); has toxic effects on hematologic, renal, GI, pulmonary, and neurologic systems; discontinue if significant drop in blood counts occurs; aspirin, NSAIDs, or low-dose steroids may be administered concomitantly with MTX (possibility of increased toxicity with NSAIDs including salicylates not tested yet)

Drug Name	Azathioprine (Imuran)
Description	Antagonizes purine metabolism and inhibits synthesis of DNA, RNA, and proteins. May decrease proliferation of immune cells, which results in lower autoimmune activity.
Adult Dose	100-150 mg/d PO initially; then 50-100 mg/d PO maintenance after improvement occurs; more accurate dosing possible with measurement of thiopurine methyltransferase level
Pediatric Dose	Not established
Contraindications	Absolute: documented hypersensitivity, pregnancy or attempting pregnancy, and clinically significant active infection Relative: Concurrent use of allopurinol; prior treatment with alkylating agents (cyclophosphamide, chlorambucil, melphalan, others) (high risk of neoplasia) Pediatric: Safety and efficacy in not established
Interactions	Allopurinol increases risk of pancytopenia; captopril/ACE inhibitors may increase risk of anemia and leukopenia; increased dose of warfarin may be necessary; may need increased dose of pancuronium for adequate paralysis; live virus vaccines, co-trimoxazole (increased risk of hematologic toxicity); rifampicin (transplants possibly rejected); clozapine (increased risk of agranulocytosis)
Pregnancy	D - Unsafe in pregnancy
Precautions	TPMT testing is not entirely reliable; it involves testing the activity of TPMT activity in RBCs, which correlates with systemic TPMT activity; functional enzyme test has been shown to have variability between test sites, and kits may contain varying amounts of enzyme inhibitor; starting at low doses, monitoring for pancytopenia, and then increasing dose is alternative; if clinical response is not good, patient may be a homozygote for high activity and may need an increased dose Possible increased risk of lymphoproliferative disorders with long-term therapy; increases risk of neoplasia; caution with liver disease and renal impairment; hematologic toxicities may occur

Drug Name	Cyclosporine (Neoral)
Description	Cyclic polypeptide that suppresses some humoral immunity and, to a greater extent, cell-mediated immune reactions such as delayed hypersensitivity, allograft rejection, experimental allergic encephalomyelitis, and graft versus host disease for a variety of organs. For children and adults, base dosing on ideal body weight.
Adult Dose	3-5 mg/kg/d PO
Pediatric Dose	Not established
Contraindications	Absolute: Significantly decreased renal function, uncontrolled hypertension, documented hypersensitivity, and clinically cured or persistent malignancy (except nonmelanoma skin cancer) Relative: Age <18 or >64 y (transplant recipients as young as 1 y have been treated with no unusual effects; however safety in patients <18 y has not been established); controlled hypertension; planning to receive a live attenuated vaccine; active infection or evidence of immunodeficiency; concurrent phototherapy, coal tar, MTX, or other immunosuppressive agents; pregnancy or lactation; unreliable patient; and severe hepatic dysfunction
Interactions	Erythromycin, clarithromycin, azithromycin, norfloxacin ciprofloxacin, cephalosporins, doxycycline, ketoconazole, itraconazole, fluconazole, ritonavir, indinavir, saquinavir, nelfinavir, diltiazem, verapamil, nicardipine, cimetidine, methylprednisolone, dexamethasone, thiazides, furosemide, allopurinol, bromocriptine, danazol, amphotericin B, metoclopramide, oral contraceptive pills, warfarin, and grapefruit juice increase levels Rifampin, rifabutin, nafcillin, carbamazepine, phenobarbital, phenytoin, valproate, octreotide, and ticlopidine decrease levels Tobramycin, gentamycin, ketoconazole, azapropazone, TMP-SMZ, vancomycin, sulindac, amphotericin B, indomethacin, naproxen, cimetidine, ranitidine, diclofenac, tacrolimus, and melphalan potentiate renal toxicity Decreased renal clearance may lead to digitalis toxicity; atorvastatin renal clearance may be –decreased, leading to myositis; methylprednisolone or prednisolone renal clearance may be decreased, leading to convulsions; concurrent ACE inhibitors, potassium supplements, and potassium-sparing diuretics may increase risk of hyperkalemia
Pregnancy	C - Safety for use during pregnancy has not been established.
Precautions	Evaluate renal and liver functions often by measuring BUN, serum creatinine, serum bilirubin, and liver enzymes; may increase risk of infection and lymphoma; reserve IV use only for those who cannot take PO

For severe acute episodes.

Drug Category: Antibiotics

For dyshidrosis with secondary impetiginization.

Drug Name	Cephalexin (Keflex)
Description	First-generation cephalosporin arrests bacterial growth by inhibiting bacterial cell wall synthesis. Bactericidal activity against rapidly growing organisms. Primary activity against skin flora; used for skin infections or prophylaxis in minor procedures.
Adult Dose	250-500 mg PO qid for 7-10 d
Pediatric Dose	25-50 mg/kg/d PO divided bid for 7-10 d (125 and 250 mg/5 mL)
Contraindications	Documented hypersensitivity
Interactions	Coadministration with aminoglycosides increases nephrotoxic potential
Pregnancy	B - Usually safe but benefits must outweigh the risks.
Precautions	Adjust dose in severe renal insufficiency (high doses may cause CNS toxicity); superinfections, and promotion of nonsusceptible organisms may occur with prolonged use or repeated therapy

Drug Name	Erythromycin (E.E.S., E-Mycin, Ery-Tab)
Description	Inhibits bacterial growth, possibly by blocking dissociation of peptidyl tRNA from ribosomes, causing RNA-dependent protein synthesis to arrest. For treatment of staphylococcal and streptococcal infections. Age, weight, and severity of infection determine proper dosage in children. When bid dosing is desired, one half of total daily dose may be taken q12h. Double the dose for more severe infections.
Adult Dose	250-500 mg PO qid for 7-10 d
Pediatric Dose	25-50 mg/kg/d PO divided qid
Contraindications	Documented hypersensitivity; hepatic impairment
Interactions	Coadministration may increase toxicity of theophylline, digoxin, carbamazepine, and cyclosporine; may potentiate anticoagulant effects of warfarin; coadministration with lovastatin and simvastatin increases risk of rhabdomyolysis
Pregnancy	B - Usually safe but benefits must outweigh the risks.
Precautions	Caution in liver disease; estolate formulation may cause cholestatic jaundice; GI side effects are common (administer pc); discontinue use if nausea, vomiting, malaise, abdominal colic, or fever occur

Drug Category: Antihistamines

To treat pruritus associated with dyshidrosis. Desloratadine (Clarinex) is a newly approved long-acting tricyclic histamine antagonist selective for H1 receptor. Is a major metabolite of loratadine, which, after ingestion, is metabolized extensively to active metabolite 3-hydroxydesloratadine. The dose for adults and children >12 y is 5 mg PO qd. Decrease dose in hepatic impairment. Limited data exist regarding drug interactions; however, erythromycin and ketoconazole increase desloratadine and 3-hydroxydesloratadine plasma concentrations, but no increase in clinically relevant adverse effects, including QTc, was observed. Adverse effects were similar to placebo, and it rarely causes pharyngitis or dry mouth.

Drug Name	Hydroxyzine (Atarax)
Description	Antagonizes H1 receptors in periphery. Sedating; may suppress histamine activity in subcortical region of CNS.
Adult Dose	10-50 mg PO q4-6h, often at bedtime
Pediatric Dose	0.5 mg/kg PO q4-6h or 10 mg/5 mL
Contraindications	Documented hypersensitivity
Interactions	CNS depression may increase with alcohol or other CNS depressants when coadministered
Pregnancy	C - Safety for use during pregnancy has not been established.
Precautions	Associated with clinical exacerbations of porphyria (may not be safe for porphyric patients); ECG abnormalities (alterations in T waves) may occur; may cause drowsiness

Drug Name	Pramoxine (Pramosone)
Description	Topical antihistamine and mild anti-inflammatory. Blocks nerve conduction and impulses by inhibiting depolarization of neurons. Available alone or as 1% or 2.5% cream or ointment. Available OTC as Prax.
Adult Dose	Topically apply cream or ointment bid/tid to affected area
Pediatric Dose	Apply as in adults <12 years: Not indicated
Contraindications	Documented hypersensitivity; do not apply over large areas and avoid contact with eyes and nose
Interactions	None reported
Pregnancy	C - Safety for use during pregnancy has not been established.
Precautions	Serious adverse reactions include anaphylactic reactions and skin sloughing (rare); common adverse reactions include contact dermatitis, edema, burning, stinging, and tenderness; caution in patients with trauma in area to be treated

Drug Category: Nickel chelators

Minimize effects of nickel in eczema.

FOLLOW-UP

Section 8 of 11  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• Multimedia
• References

Further Outpatient Care

• Schedule follow-up and check blood pressure 1 week after initiating prednisone.

Deterrence/Prevention

• Advise patients to avoid known contact irritants or allergens.
• Advise patients to reduce stress (may help some patients).
• Advise patients to follow a hand care regimen.
• Advise regular prophylactic use of emollients.

Complications

• Secondary bacterial infection of vesicles or bullae can result in cellulitis, lymphangitis, and septicemia (rare).
• Dystrophic nail changes may develop with transverse ridging, thickening, discoloration, and pitting of nails.

Prognosis

• Dyshidrotic eczema follows a chronic intermittent course. Fewer episodes occur after middle age.

Patient Education

• Instruct patients to avoid contact with certain allergens or irritants (eg, nickel).
• Instruct patients to follow a hand care routine that avoids irritants.
• Instruct patients to use emollients regularly.
• For excellent patient education resources, visit eMedicine's Skin, Hair and, Nails Center. Also, see eMedicine's patient education article Eczema.

MISCELLANEOUS

Section 9 of 11  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• Multimedia
• References

Medical/Legal Pitfalls

• Failure to guard against or inform patients of the potential development of systemic corticosteroid side effects with prolonged use of systemic steroids (eg, hypertension, diabetes mellitus, weight gain, cataracts, osteoporosis)
• Failure to acquire an adequate history of exposure to potential allergic and irritant contactants (contactants at patient's work may be a contributing factor or cause recurrent episodes)
• Failure to consider other possible diagnoses

Special Concerns

• Substances used to systemically challenge patients with possible ingested allergens may trigger exacerbations. Vasculitis or erythema multiforme may develop during this testing.

MULTIMEDIA

Section 10 of 11  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• Multimedia
• References

Media file 1:  Tense vesicles and bullae on the palm. Courtesy of Norman Minars, MD, University of Miami, Department of Dermatology & Cutaneous Surgery.
	View Full Size Image
Media type:  Photo

Media file 2:  Close-up view of tense vesicles and bullae of the palm. Courtesy of Norman Minars, MD, University of Miami, Department of Dermatology & Cutaneous Surgery.
	View Full Size Image
Media type:  Photo

Media file 3:  Discrete yellow pustules on the sole of the foot. Courtesy of Norman Minars, MD, University of Miami, Department of Dermatology & Cutaneous Surgery.
	View Full Size Image
Media type:  Photo

Media file 4:  Multiple tense vesicles on the palm.
	View Full Size Image
Media type:  Photo

Media file 5:  Small tense vesicles on the fingers.
	View Full Size Image
Media type:  Photo

Media file 6:  Small, discrete, coalesced vesicles on the dorsal hand.
	View Full Size Image
Media type:  Photo

Media file 7:  Small, discrete, coalesced vesicles on the fingers.
	View Full Size Image
Media type:  Photo

Media file 8:  Palms and soles of a patient with a dyshidrosis flare. The patient unroofed a large bulla on the right sole.
	View Full Size Image
Media type:  Photo

Media file 9:  Small discrete vesicles of the lateral fingers.
	View Full Size Image
Media type:  Photo

REFERENCES

Section 11 of 11

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• Multimedia
• References

• Burdick AE. Pompholyx. In: Lebwohl MG, Heymann WR , Berth-Jones J, eds. Treatment of Skin Disease: Comprehensive Therapeutic Strategies. London, England: Mosby; 2006:509-510.
• Capella GL. Topical khellin and natural sunlight in the outpatient treatment of recalcitrant palmoplantar pompholyx: report of an open pilot study. Dermatology. 2005;211(4):381-3. [Medline].
• Chen JJ, Liang YH, Zhou FS, Yang S, Wang J, Wang PG, et al. The gene for a rare autosomal dominant form of pompholyx maps to chromosome 18q22.1-18q22.3. J Invest Dermatol. Feb 2006;126(2):300-4. [Medline].
• Colebunders R, Zolfo M, Lynen L. Severe dyshidrosis in two patients with HIV infection shortly after starting highly active antiretroviral treatment. Dermatol Online J. 2005;11(2):31. [Medline].
• Crosti C, Lodi A. Pompholyx: a still unresolved kind of eczema. Dermatology. 1993;186(4):241-2. [Medline].
• Dover JS. Pocket Guide to Cutaneous Medicine and Surgery. Philadelphia, Pa: WB Saunders; 1996.
• Egan CA, Rallis TM, Meadows KP, Krueger GG. Low-dose oral methotrexate treatment for recalcitrant palmoplantar pompholyx. J Am Acad Dermatol. Apr 1999;40(4):612-4. [Medline].
• Iannaccone S, Sferrazza B, Quattrini A, Smirne S, Ferini-Strambi L. Pompholyx (vesicular eczema) after i.v. immunoglobulin therapy for neurologic disease. Neurology. Sep 22 1999;53(5):1154-5. [Medline].
• Jain VK, Aggarwal K, Passi S, Gupta S. Role of contact allergens in pompholyx. J Dermatol. Mar 2004;31(3):188-93. [Medline].
• Kim YJ, Kim MY, Kim HO, Park YM. Dyshidrosiform bullous pemphigoid. Acta Derm Venereol. 2004;84(3):253-4. [Medline].
• Koldys KW, Meyer RP. Biofeedback training in the therapy of dyshidrosis. Cutis. Aug 1979;24(2):219-21. [Medline].
• Konstantopoulou M, Belgi A, Griffiths KD, Seale JR, Macfarlane AW. Azathioprine-induced pancytopenia in a patient with pompholyx and deficiency of erythrocyte thiopurine methyltransferase. BMJ. Feb 12 2005;330(7487):350-1. [Medline].
• Levine N. Pruritic rash of the hands and feet. Geriatrics. Jun 1997;52(6):29. [Medline].
• Lodi A, Betti R, Chiarelli G, Urbani CE, Crosti C. Epidemiological, clinical and allergological observations on pompholyx. Contact Dermatitis. Jan 1992;26(1):17-21. [Medline].
• Magina S, Barros MA, Ferreira JA, Mesquita-Guimaraes J. Atopy, nickel sensitivity, occupation, and clinical patterns in different types of hand dermatitis. Am J Contact Dermat. Jun 2003;14(2):63-8. [Medline].
• Man I, Ibbotson SH, Ferguson J. Photoinduced pompholyx: a report of 5 cases. J Am Acad Dermatol. Jan 2004;50(1):55-60. [Medline].
• Menné T, Kaaber K. Treatment of pompholyx due to nickel allergy with chelating agents. Contact Dermatitis. Oct 1978;4(5):289-90. [Medline].
• Odia S, Vocks E, Rakoski J, Ring J. Successful treatment of dyshidrotic hand eczema using tap water iontophoresis with pulsed direct current. Acta Derm Venereol. Nov 1996;76(6):472-4. [Medline].
• Ogden S, Clayton TH, Goodfield MJ. Recalcitrant hand pompholyx: variable response to etanercept. Clin Exp Dermatol. Jan 2006;31(1):145-6. [Medline].
• Papadopoulos EJ, Jaffe ES, Elgart GW, Raffeld M, Turner ML. Periodic fever with atypical dyshidrosis--quiz case. Arch Dermatol. Apr 2004;140(4):479-84. [Medline].
• Petering H, Breuer C, Herbst R, Kapp A, Werfel T. Comparison of localized high-dose UVA1 irradiation versus topical cream psoralen-UVA for treatment of chronic vesicular dyshidrotic eczema. J Am Acad Dermatol. Jan 2004;50(1):68-72. [Medline].
• Petersen CS, Menne T. Cyclosporin A responsive chronic severe vesicular hand eczema. Acta Derm Venereol. Nov 1992;72(6):436-7. [Medline].
• Pitche P, Boukari M, Tchangai-Walla K. [Factors associated with palmoplantar or plantar pompholyx: a case-control study]. Ann Dermatol Venereol. Feb 2006;133(2):139-43. [Medline].
• Polderman MC, Govaert JC, le Cessie S, Pavel S. A double-blind placebo-controlled trial of UVA-1 in the treatment of dyshidrotic eczema. Clin Exp Dermatol. Nov 2003;28(6):584-7. [Medline].
• Rietschel RL, Fowler JF. Fisher's Contact Dermatitis. 4^th ed. Baltimore, Md: Williams & Wilkins; 1995:332-45.
• Scerri L. Azathioprine in dermatological practice. An overview with special emphasis on its use in non-bullous inflammatory dermatoses. Adv Exp Med Biol. 1999;455:343-8. [Medline].
• Vocks E, Plotz SG, Ring J. The Dyshidrotic Eczema Area and Severity Index - A score developed for the assessment of dyshidrotic eczema. Dermatology. 1999;198(3):265-9. [Medline].
• Wilkinson JD. Vesicular palmoplantar eczema. In: Freedburg IM, Eisen AZ, Wolff K, eds. Fitzpatrick's Dermatology in General Medicine. 5^th ed. New York, NY: McGraw-Hill; 1999:1489-94.
• Wollina U, Abdel Naser MB. Pharmacotherapy of pompholyx. Expert Opin Pharmacother. Jul 2004;5(7):1517-22. [Medline].
• Wollina U, Karamfilov. Adjuvant botulinum toxin A in dyshidrotic hand eczema: a controlled prospective pilot study with left-right comparison. J Eur Acad Dermatol Venereol. Jan 2002;16(1):40-2. [Medline].

Article Last Updated: Jun 8, 2007